For Pseudomonas aeruginosa. Sold as Azactam, Azactam In Plastic Container, Cayston. Every FDA application for this active ingredient: 3 branded and 4 generic.
As of Nov 14, 2026, FDA lists 7 applications for Aztreonam (sold as Azactam, Azactam In Plastic Container, Cayston), first approved Dec 31, 1986, with 2 new uses approved and 0 published complete response letters.
| Aztreonam | Part D | $2.6M | +9% | 1,595 |
| Azactam | Part D | $100K | -6% | 107 |
| Azactam | Part B | $41K | -65% | 47 |
| Real-world Effectiveness of Cefiderocol Versus Aztreonam/AvibactamMetallo-β-lactamase-producing · University Hospital Virgen de las Nieves | — | Active, not recruiting | Nov 2, 2026 |
| Aztreonam-Avibactam in Immunocompromised HostsEnterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection · Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | — | Recruiting | Oct 22, 2026 |
| Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver TransplantationLiver Transplant, Carbapenem-resistant Enterobacterales · IRCCS Azienda Ospedaliero-Universitaria di Bologna | Phase 3 | Not yet recruiting | Aug 12, 2026 |
| Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNBCeftazidime-avibactam, Aztreonam · Jing Zhou | Phase 4 | Recruiting | Mar 17, 2026 |
| Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled TrialCritical Illness, Mechanical Ventilation · University of Calgary | Phase 2 | Not yet recruiting | Mar 11, 2026 |
| Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CREComplicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP) · Sir Run Run Shaw Hospital | — | Recruiting | Dec 8, 2025 |
| Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of CareFebrile Urinary Tract Infection · Uppsala University | Phase 4 | Recruiting | Nov 19, 2025 |
| Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.Febrile Neutropenia · Shanxi Bethune Hospital | — | Recruiting | Oct 2, 2025 |
| Dec 31, 1986 | AzactamNDA 50580 · New molecular entity | Labs Delbert | 27 | Marketed |
| May 24, 1989 | Azactam In Plastic ContainerNDA 50632 · New dosage form | Bristol Myers Squibb | 14 | Discontinued |
| Feb 22, 2010 | CaystonNDA 50814 · New dosage form | Gilead | 11 | Marketed |
| Jun 18, 2010 | AztreonamANDA 65439 | Fresenius Kabi USA | 4 | Marketed |
| Mar 23, 2011 | AztreonamANDA 65286 | Hikma | 1 | Discontinued |
| Nov 8, 2021 | AztreonamANDA 206517 | Hospira | 1 | Marketed |
| Feb 5, 2026 | AztreonamANDA 207069 | Hikma | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Bristol Myers Squibb
Fresenius Kabi USA
Hikma